Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970064 | 0.79 | TUBB4A (0.34) | MEN1NPC1RAB9AKMT2AAGTR1 | |
| SCHEMBL4176153 | 0.78 | ALDH1A1 (0.42) | MEN1NPC1RAB9AKMT2AAGTR1 | |
| SCHEMBL4180685 | 0.78 | NQO2 (0.49) | MEN1NPC1RAB9AKMT2AAGTR1 | |
| SCHEMBL4173484 | 0.78 | MCHR1 (0.36) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4700675 | 0.73 | LMNA (0.52) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL16106494 | 0.71 | CCR1 (0.35) | — | |
| SCHEMBL29091679 | 0.70 | SLC6A3 (0.34) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL6844002 | 0.70 | CCR1 (0.43) | RAB9AKMT2A | |
| SCHEMBL9873091 | 0.70 | KDM4E (0.43) | KMT2ACA12CA1CA7CA9 | |
| SCHEMBL27498077 | 0.69 | RET (0.33) | ESR1ESR2MEN1KMT2AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| CN-101258129-A | Quinoline derivatives and use as antitumor agents | UNIV WAYNE STATE (US) | 2008-09-03 | — | — | CN | disclosed |
| EP-1940794-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007030780-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030780-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | disclosed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | disclosed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060612-A1 | Antitumor agents | TP53, NHERF1, MCL1 | ESR1 4795/4885ESR2 4765/4885MEN1 38/4885 |
| US-20090069372-A1 | ANTITUMOR AGENTS | NHERF1, BACH1, MCL1 | ESR1 4794/4885ESR2 4753/4885MEN1 76/4885 |
| US-20070054938-A1 | Antitumor agents | TP53, NHERF1, MCL1 | ESR1 4795/4885ESR2 4765/4885MEN1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.